Alto Neuroscience Secures U.S. Patent No. 12,521,374
Alto Neuroscience announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron. The patent protects an aspect of ALTO-207 - the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole.
